Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

ESC

INTERVENTIONAL

COMMUNITY

EARLY CAREER INVOLVEMENT

134 - CCS/ESC JOINT PLENARY: STRUCTURAL HEART TEAM INTERVENTIONS: FOCUS ON THE AORTIC VALVE

Thursday, October 24, 2024
11:00 AM – 12:00 PM PT
Room: 211
On-Demand Early Career Involvement
Looking for more information? Check out the latest CCS journals article collection on structural heart team interventions.

Learning Objectives:

At the end of this session participants will be able to:
  • assess the severity and suitability of percutaneous vs surgical aortic valve replacement;
  • identify the multimodality imaging required for the evaluation of the aortic valve;
  • compare the risks vs benefits of percutaneous and surgical aortic valve interventions; and
  • discuss the potential complications of multiple or early percutaneous valves.
Disclosure(s):
Michelle M. Graham, MD: No financial relationships to disclose
Anil Gupta, MD, FRCPC: No financial relationships to disclose
Negareh Mousavi, M.D.: No financial relationships to disclose
Wendy Tsang, MD, FRCPC: Abbott: Honoraria (Terminated, December 31, 2023); Philips: Research support (Ongoing); Siemens: Research equipment (Ongoing); UpToDate: Honoraria (Ongoing)
Maral Ouzounian, MD PhD: Antonio & Helga DeGasperis Chair in Clinical Trials and Outcomes Research: Funded Chair (Ongoing); Munk Chair in Advanced Therapeutics: Chair (Ongoing)
Ralph Stephan von Bardeleben: Abbott Laboratories: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Edwards Lifesciences: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Jenscare: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Medtronic: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Philips: Speaker/Honoraria (Ongoing); Siemens: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); University Göttingen IZKS: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Atul Verma, MD FRCPC FHRS: Abbott: Pre-clinical work (Ongoing); Biosense Webster: Advisory board (Ongoing), IIS grant (Ongoing); Medtronic: Advisory board (Ongoing), IIS grant (Ongoing)
Filio Billia, MD PhD FRCPC FACC: Abbottt Laboratories: physician-initiated research funding (Ongoing)
Margot K. Davis, MD, MSc, FRCPC: Abbott: Speaking honoraria (Ongoing); Alnylam: advisory board honoraria (Ongoing); Anthos: Ad board honoraria (Ongoing); AstraZeneca: Ad board honoraria (Ongoing), Research steering committee, research funding (Ongoing); BI-Lilly: Ad board honoraria (Ongoing); Ferring: Ad board honoraria (Ongoing), Speaking honoraria (Ongoing); Janssen: Ad board honoraria (Ongoing), Consulting and speaking honoraria (Ongoing), Research funding (Ongoing); Jazz Pharmaceuticals: Ad board honoraria (Ongoing); Novo Nordisk: Advisory board honoraria (Ongoing), Consulting fees (Ongoing); Pfizer: consulting honoraria (Ongoing), research funding (Ongoing), speaking and consulting honoraria (Ongoing)
Tara D'Ignazio: No financial relationships to disclose
Robin A. Ducas, MD, FRCPC: No financial relationships to disclose
Jonathan Howlett: aAstraZeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); Novartis: Consultant/Advisory Board (Terminated, June 28, 2024); Novo Nordksk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Varinder K. Randhawa, MD PhD: No financial relationships to disclose
Paaladinesh Thavendiranathan, MD, SM, FRCPC, FASE: No financial relationships to disclose